Cancer treatment reviews最新文献

{"title":"EORTC consensus recommendations on the optimal management of colorectal cancer liver metastases","authors":"Giacomo Bregni ,&nbsp;Richard Adams ,&nbsp;Reto Bale ,&nbsp;Maria A Bali ,&nbsp;Irene Bargellini ,&nbsp;Lennart Blomqvist ,&nbsp;Gina Brown ,&nbsp;Chiara Cremolini ,&nbsp;Pieter Demetter ,&nbsp;Timm Denecke ,&nbsp;Anthony Dohan ,&nbsp;Cristina Dopazo ,&nbsp;Elena Elez ,&nbsp;Serge Evrard ,&nbsp;Roger Feakins ,&nbsp;Matthias Guckenberger ,&nbsp;Marianne Gronlie Guren ,&nbsp;Maria Hawkins ,&nbsp;Anne Hoorens ,&nbsp;Emmanuel Huguet ,&nbsp;Francesco Sclafani","doi":"10.1016/j.ctrv.2025.102926","DOIUrl":"10.1016/j.ctrv.2025.102926","url":null,"abstract":"<div><div>Patients with colorectal cancer liver metastases have long represented a unique and thoroughly investigated population. Nevertheless, the optimal management of these is still controversial with a number of open questions which are only partially addressed by available studies and existing guidelines. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Tract Cancer Group (GITCG) sought to fill this knowledge gap and promoted the development of a European consensus on this subject. By using the Delphi methodology and leveraging a multidisciplinary team of 43 international experts, including gastrointestinal oncologists, hepatobiliary surgeons, interventional radiologists, radiation oncologists, radiologists, nuclear medicine physicians and pathologists from 12 European countries, 34 practical recommendations and two consensus statements were proposed. These cover varying aspects of the optimal management of colorectal cancer liver metastases such as baseline imaging, selection criteria for liver-directed therapies, treatment strategies, assessment of treatment response, follow-up, care delivery, clinical research and future perspectives. This roadmap document is intended to complement national and international guidelines, and to provide practical guidance for clinicians and multidisciplinary teams, ultimately promoting practice standardisation, optimal management and better patient outcomes across Europe. Also, it provides a unique opportunity to highlight grey areas and unmet needs, and to give a strategic direction to future research in the field by identifying topics where there is no consensus among experts.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"136 ","pages":"Article 102926"},"PeriodicalIF":9.6,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143759336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies","authors":"Teresa Alonso-Gordoa ,&nbsp;Georgia Anguera ,&nbsp;Mario Domínguez-Esteban ,&nbsp;Òscar Reig ,&nbsp;Hilario Martínez-Barros ,&nbsp;Javier Molina-Cerrillo ,&nbsp;Patricia Cruz ,&nbsp;Pablo Maroto","doi":"10.1016/j.ctrv.2025.102925","DOIUrl":"10.1016/j.ctrv.2025.102925","url":null,"abstract":"<div><div>Immunotherapy has changed the management of localized clear cell renal cell carcinoma (ccRCC) since the approval of adjuvant pembrolizumab, which demonstrated significant improvements in disease-free survival (DFS) and overall survival (OS) in patients at intermediate and high risk of recurrence. This new approach impacts rescue strategies in patients who relapse after local treatment and during or after adjuvant pembrolizumab. Nevertheless, there is currently no robust scientific evidence on therapeutic decision-making in this clinical situation, representing an area for further debate and research.</div><div>In this article, a group of experts from the Genitourinary Alliance for Research and Development (GUARD) have reviewed the available scientific evidence to establish the basis for therapeutic decision-making in patients with ccRCC who progress after adjuvant treatment with immunotherapy. Despite the lack of randomized clinical trials in this setting, this group of experts recommends classifying patients according to relapse volume (oligometastatic <em>vs</em>. polymetastatic), time to relapse and certain molecular characteristics. Rescue treatments beyond relapse should be individualized and might include locoregional treatments such as surgery or radiotherapy as well as antiangiogenic therapies in patients defined as resistant to immunotherapy.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"136 ","pages":"Article 102925"},"PeriodicalIF":9.6,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143776889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?","authors":"Arthur Géraud ,&nbsp;Paul Gougis ,&nbsp;Alexandre de Nonneville ,&nbsp;Mathilde Beaufils ,&nbsp;François Bertucci ,&nbsp;Emilien Billon ,&nbsp;Gabriel Brisou ,&nbsp;Gwenaelle Gravis ,&nbsp;Laurent Greillier ,&nbsp;Mathilde Guerin ,&nbsp;Essia Mezni ,&nbsp;Emmanuel Mitry ,&nbsp;Robin Noel ,&nbsp;Joséphine Pignon ,&nbsp;Renaud Sabatier ,&nbsp;Lorène Seguin ,&nbsp;Jean-Philippe Spano ,&nbsp;Cécile Vicier ,&nbsp;Frederic Viret ,&nbsp;Anthony Goncalves ,&nbsp;Joseph Ciccolini","doi":"10.1016/j.ctrv.2025.102922","DOIUrl":"10.1016/j.ctrv.2025.102922","url":null,"abstract":"<div><div>Antibody-drug conjugates (ADCs) are a rising therapeutic class in oncology and hematology, with eleven drugs approved by the US Food and Drug Administration as of January 2025. These “magic bullets” have a complex structure, including a monoclonal antibody, a linker, attachment sites, and a payload usually disrupting microtubules, targeting DNA, or inhibiting topoisomerase 1. By targeting specific tumor antigens, they are expected to be exquisitely effective in releasing “supertoxic” payloads inside tumor cells after intracellular trafficking. Additionally, they may exert a bystander effect, wherein the released payloads act on neighboring cells, amplifying their therapeutic impact regardless of target expression. ADCs have been game-changing drugs to treat tumors with once dismal prognoses or with previously considered unactionable targets, such as HER2-low or triple-negative breast cancer. To what extent there is room for personalized medicine to improve the toxicity/efficacy ratio remains unknown. However, there are inherent issues related to the complexity of the pharmacokinetics of ADCs and their assessments: efficacy or toxicity may be influenced by the clearance of the intact ADC, the circulating payload, or the payload-linker complex. Deciphering these multifaceted exposure-outcomes relationships for both efficacy and safety endpoints, is critical for advancing precision medicine and enabling personalized dosing strategies. To improve future developments and broaden their therapeutic scope, several strategies can be developed, including developing adequate combinations with other treatment classes (cytotoxic agents, immune-checkpoint inhibitors, oral molecular-targeted therapies). In this review, we will discuss the PK/PD aspects of ADCs and their dosing to improve their use in current and future indications.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"135 ","pages":"Article 102922"},"PeriodicalIF":9.6,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143715270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer","authors":"Taha Koray Sahin ,&nbsp;Alessandro Rizzo ,&nbsp;Deniz Can Guven ,&nbsp;Sercan Aksoy","doi":"10.1016/j.ctrv.2025.102924","DOIUrl":"10.1016/j.ctrv.2025.102924","url":null,"abstract":"<div><div>The combination of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) is the standard first-line treatment for hormone receptor-positive (HR + ) and HER2-negative metastatic breast cancer (mBC). Despite their efficacy, resistance inevitably develops, necessitating alternative therapeutic strategies post-progression. This review explores current and emerging treatment options following progression on CDK4/6i, focusing on endocrine therapies, targeted therapies, combination approaches, and the continued use of CDK4/6i. Endocrine therapies, including fulvestrant and novel oral selective estrogen receptor degraders (SERDs) like elacestrant, show promise, especially in patients with <em>ESR1</em> mutations. Targeted therapies such as <em>PI3K/AKT/mTOR</em> inhibitors, exemplified by alpelisib and capivasertib, offer potential by addressing downstream signaling pathways involved in resistance. Additionally, FGFR inhibitors like erdafitinib are under investigation for their role in overcoming specific resistance mechanisms. Combination strategies involving CDK4/6 inhibitors with immune checkpoint inhibitors or other targeted agents are also being explored, with early trials suggesting possible synergistic effects, although further validation is required. Continuation of CDK4/6 inhibitors beyond progression has shown potential benefits in selected patients, but the data are heterogeneous, and further studies are needed to clarify their role. While chemotherapy remains a standard option for patients who progress on these treatments, the goal is to delay its use through the effective utilization of endocrine and targeted therapies. Understanding resistance mechanisms and tailoring treatment to individual patient profiles is crucial for optimizing outcomes. Ongoing clinical trials are expected to provide deeper insights, guiding the development of more effective post-progression therapeutic strategies. This evolving landscape highlights the need for continuous research and individualized patient care to improve survival and quality of life in HR + mBC patients.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"135 ","pages":"Article 102924"},"PeriodicalIF":9.6,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143685587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of loss of HER2 positivity following neoadjuvant therapy in HER2-positive breast cancer patients on long-term prognosis: A systematic review and meta-analysis","authors":"Shunsuke Nakatani ,&nbsp;Takuya Hayashi ,&nbsp;Keiko Yamamoto ,&nbsp;Hideki Maeda","doi":"10.1016/j.ctrv.2025.102923","DOIUrl":"10.1016/j.ctrv.2025.102923","url":null,"abstract":"<div><h3>Aims</h3><div>The primary objective was to assess the impact of HER2 loss after neoadjuvant therapy on the long-term prognosis of patients with HER2-positive breast cancer.</div></div><div><h3>Methods</h3><div>We extracted relevant studies from PubMed and Cochrane Library and performed systematic review and <em>meta</em>-analysis. The key eligibility criteria for the studies were as follows: included HER2-positive early breast cancer cases undergoing neoadjuvant therapy, available data on HER2 status before and after neoadjuvant therapy, and reported recurrence-related outcomes (disease-free survival/invasive disease-free survival/relapse-free survival) or overall survival.</div></div><div><h3>Results</h3><div>Of 915 studies that were initially identified, 8 met the eligibility criteria and were included in the <em>meta</em>-analysis for the recurrence-related outcomes (1,917 patients with HER2 loss: 411 [21.4 %] or HER2 retained: 1,506 [78.6 %]); 4 of them reported data on overall survival (606 patients with HER2 loss: 243 [40.1 %] or HER2 retained: 363 [59.9 %]). The average follow-up duration, based on data from five out of eight studies that reported this information, was 51.6 months. HER2 loss was significantly associated with worse recurrence-related outcomes (hazards ratio [HR] 1.85, 95 % confidence interval [CI] 1.31–2.61, p = 0.0005) and worse overall survival (HR 2.37, 95 % CI 1.27–4.41, p = 0.0065). No heterogeneity or publication bias was observed in the <em>meta</em>-analysis.</div></div><div><h3>Conclusions</h3><div>This study demonstrated that compared with patients with HER2 retained, those with HER2 loss had significantly higher risk of disease recurrence and worse prognosis. These findings implied the possible use of HER2 loss as a prognostic factor in patients with HER2-positive early breast cancer. Reassessment of HER2 status after neoadjuvant therapy could be valuable in predicting prognosis and may lead to reconsideration of the rational subsequent treatment.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"135 ","pages":"Article 102923"},"PeriodicalIF":9.6,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143672002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The evolving landscape of stage III unresectable non-small cell lung cancer “between lights and shadows”","authors":"Marco Donatello Delcuratolo ,&nbsp;Veronica Crespi ,&nbsp;Giorgio Saba ,&nbsp;Andrea Mogavero ,&nbsp;Valerio Maria Napoli ,&nbsp;Edoardo Garbo ,&nbsp;Massimiliano Cani ,&nbsp;Antonio Ungaro ,&nbsp;Maria Lucia Reale ,&nbsp;Alessandra Merlini ,&nbsp;Enrica Capelletto ,&nbsp;Paolo Bironzo ,&nbsp;Mario Levis ,&nbsp;Umberto Ricardi ,&nbsp;Silvia Novello ,&nbsp;Francesco Passiglia","doi":"10.1016/j.ctrv.2025.102918","DOIUrl":"10.1016/j.ctrv.2025.102918","url":null,"abstract":"<div><div>Despite PACIFIC set a new milestone in the clinical management of unresectable stage III non-small cell lung cancer (NSCLC), it left some critical questions pending for clinical research: the efficacy of durvalumab in the real-world setting; the activity of less intensive regimens for frail populations; the role of targeted therapies in oncogene-addicted tumors; the selection of subsequent strategies at immunotherapy failure; the efficacy of novel and intensified treatments; the role of molecular biomarkers for patients’ selection. This review aims to describe the evolving landscape of unresectable stage III NSCLC and provides an updated overview of the available evidence, analyzing lights and shadows emerging from recent clinical trials and discussing the most relevant challenges of post-PACIFIC era.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"135 ","pages":"Article 102918"},"PeriodicalIF":9.6,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143609886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-line treatment of locally advanced cervical carcinoma: An updated systematic review and Bayesian network meta-analysis","authors":"Fausto Petrelli ,&nbsp;Valentina Riboldi ,&nbsp;Lorenza Bruschieri ,&nbsp;Antonella Villa ,&nbsp;Fulvia Milena Cribiu’ ,&nbsp;Karen Borgonovo ,&nbsp;Mara Ghilardi ,&nbsp;Antonio Ghidini ,&nbsp;Silvia Seghezzi ,&nbsp;Agostina De Stefani ,&nbsp;Francesca Trevisan","doi":"10.1016/j.ctrv.2025.102921","DOIUrl":"10.1016/j.ctrv.2025.102921","url":null,"abstract":"<div><h3>Introduction</h3><div>Locally advanced cervical carcinoma (LACC) remains a significant global health issue, particularly in low- and middle-income countries (LMICs), where disease burden is highest. While cisplatin-based chemoradiotherapy (CTRT) has long been the cornerstone of first-line treatment, its toxicities, including nephrotoxicity and hematologic adverse events, limit its use in certain patients. Advances in systemic therapies, including immune checkpoint inhibitors and induction chemotherapy, offer new avenues for improving outcomes. This study aimed to evaluate the efficacy of various first-line regimens for LACC through a systematic review and Bayesian network <em>meta</em>-analysis (NMA), focusing on overall survival (OS) and progression-free survival (PFS).</div></div><div><h3>Materials and Methods</h3><div>This analysis adhered to PRISMA guidelines and included Phase III randomized controlled trials (RCTs) evaluating first-line treatments for LACC. The primary outcome was OS, expressed as hazard ratios (HRs) with 95% confidence intervals (CIs), while PFS was secondary. A comprehensive search of PubMed, EMBASE, and Cochrane Library was conducted through November 2024. Statistical analysis used a Bayesian NMA framework, with treatments ranked by surface under the cumulative ranking curve (SUCRA).</div></div><div><h3>Results</h3><div>Pembrolizumab + CTRT improved OS (HR, 0.67; 95 % CI, 0.50–0.90), while induction chemotherapy with carboplatin/paclitaxel followed by CTRT showed significant benefit (HR, 0.60; 95 % CI, 0.40–0.90). RT + cisplatin and 5-fluorouracil (5-FU) also improved OS (HR, 0.66; 95 % CI, 0.44–0.99), ranking highest in SUCRA analysis (98 %).</div></div><div><h3>Conclusion</h3><div>Three promising strategies—pembrolizumab-based regimens, induction chemotherapy followed by CTRT, and RT + CDDP + 5-FU—offer substantial survival benefits, advancing treatment options for LACC.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"135 ","pages":"Article 102921"},"PeriodicalIF":9.6,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143609887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From Dose-Finding to Dose-Optimization in Early-Phase oncology clinical trials","authors":"Elvina Almuradova ,&nbsp;Davide Izzo ,&nbsp;Sara Gandini ,&nbsp;Aurora Gaeta ,&nbsp;Edoardo Giordano ,&nbsp;Carmine Valenza ,&nbsp;Gabriele Antonarelli ,&nbsp;Dario Trapani ,&nbsp;Giuseppe Curigliano","doi":"10.1016/j.ctrv.2025.102906","DOIUrl":"10.1016/j.ctrv.2025.102906","url":null,"abstract":"<div><div>Dose optimization in Phase I oncology trials balances therapeutic efficacy and patient safety. Traditional dose-escalation methods, such as the 3 + 3 design, primarily focus on safety, often resulting in prolonged exposure to subtherapeutic or excessively toxic doses. Additionally, these methods may fail to account for modern therapies’ complex pharmacokinetics and pharmacodynamics, including targeted agents and immunotherapies.</div><div>Contemporary approaches address these gaps by incorporating biomarkers, pharmacokinetic profiling, and patient-reported outcomes to guide personalized dosing strategies. Such methods improve the precision of dose selection and promote individualized cancer care. This review underscores the importance of distinguishing between dose-finding and dose optimization, advocating for designs that integrate patient perspectives and pharmacologic insights from early-phase trials. Additionally, we highlight the challenges of traditional methodologies and the importance of simplifying complex designs without compromising their scientific rigor. By embracing innovative approaches and patient-centered metrics, Phase I trials can evolve beyond safety assessments to expedite the delivery of effective and tailored cancer therapies.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"136 ","pages":"Article 102906"},"PeriodicalIF":9.6,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis","authors":"Tarek Assi ,&nbsp;Tania Moussa ,&nbsp;Carine Ngo ,&nbsp;Matthieu Faron ,&nbsp;Benjamin Verret ,&nbsp;Antonin Lévy ,&nbsp;Charles Honoré ,&nbsp;Clémence Hénon ,&nbsp;Cécile Le Péchoux ,&nbsp;Rastilav Bahleda ,&nbsp;Julien Vibert ,&nbsp;Axel Le Cesne","doi":"10.1016/j.ctrv.2025.102904","DOIUrl":"10.1016/j.ctrv.2025.102904","url":null,"abstract":"<div><div>Tenosynovial giant cell tumor is a non-malignant primary locally aggressive articular disease that affects the synovium of joints, tendon sheaths, and bursae. It is characterized by a translocation t (1;2), leading to the overexpression of CSF1 in the tumor microenvironment. CSF1 induces the recruitment of non-malignant cells, mainly macrophages, followed by the differentiation and polarization of these cells into the M2 phenotype. Surgery, particularly total synovectomy, remains the cornerstone of TGCT management. However, recurrence rates vary, reaching 40 to 60% in diffuse disease, often resulting in progressive joint dysfunction, pain, and potential need for joint replacement or limb amputation. Systemic therapy is recommended in recurrent TGCT in patients not amenable to additional surgery. Targeting the CSF1/CSF1R axis has successfully improved tumor responses and enhanced symptomatic function. In this review, we aim to explore contemporary paradigms in inoperable TGCT patients, with a focus on the physiopathology, clinical efficacy, and safety of CSF1 or CSF1R inhibitors.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"134 ","pages":"Article 102904"},"PeriodicalIF":9.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment decision-making factors and sequencing in recurrent and/or metastatic squamous cell carcinoma of the head and neck","authors":"Petr Szturz ,&nbsp;Thorsten Fuereder ,&nbsp;Ye Guo ,&nbsp;Lisa Licitra ,&nbsp;Ricard Mesia ,&nbsp;Philipp Ivanyi ,&nbsp;Agustin Falco ,&nbsp;Makoto Tahara ,&nbsp;Marie-Noelle Solbes ,&nbsp;Filippo Venturini ,&nbsp;Paolo Bossi","doi":"10.1016/j.ctrv.2025.102910","DOIUrl":"10.1016/j.ctrv.2025.102910","url":null,"abstract":"<div><div>Treatment options for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) have evolved over the past decade and have helped improve survival outcomes for patients. Most national and regional guidelines recommend first-line therapy with an immune checkpoint inhibitor (with or without chemotherapy) or a cetuximab-based regimen, by assessment of expression levels of the biomarker programmed cell death-ligand 1 (PD-L1). However, patient- and tumor-specific factors, including the patient’s age, comorbidities, performance status, and tumor burden, kinetics and spread also need to be considered to optimize treatment in the first line. Additionally, with increasing availability of newer therapies globally, it is crucial to customize the subsequent second- or later-line therapy based on patient characteristics, including the previous therapy received. This review highlights the factors that should be considered for treatment decision-making in patients with R/M SCCHN. It also summarizes the current evidence for clinical outcomes based on treatment sequencing and provides guidance on choosing an optimal treatment regimen for patients in the first-line treatment setting and beyond.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"135 ","pages":"Article 102910"},"PeriodicalIF":9.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}